🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying

Published 28/02/2024, 14:06
© Reuters.  $7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying
VFC
-
OCUL
-
WES
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

V.F. Corporation

  • The Trade: V.F. Corporation (NYSE: VFC) Director Richard Carucci acquired a total of 20,000 shares an average price of $15.53. To acquire these shares, it cost around $310,620.
  • What’s Happening: VF Corp expanded board with appointment of Caroline Brown following engagement with Engaged Capital.
  • What V.F. Corporation Does: VF designs, produces, and distributes branded apparel, footwear, and accessories.
Western Midstream Partners
  • The Trade: Western Midstream Partners, LP (NYSE: WES) Director Kenneth F. Owen acquired a total of 7,000 shares at an average price of $33.96. To acquire these shares, it cost around $237,720.
  • What’s Happening: On Feb. 21, Western Midstream Partners reported a year-over-year increase in fourth-quarter revenue results.
  • What Western Midstream Partners Does: Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets.
Don’t forget to check out our premarket coverage here

Ocular Therapeutix

  • The Trade: Ocular Therapeutix, Inc. (NASDAQ: OCUL) 10% owner Summer Road LLC bought a total of 930,851 shares at an average price of $7.52. To acquire these shares, it cost around 7 million.
  • What’s Happening: On Feb. 22, Ocular Therapeutix announced a $325 million private placement.
  • What Ocular Therapeutix Does: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye.

Check This Out: Investor Sentiment Improves Following Economic Reports; S&P 500 Settles Higher

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.